$6.47 Billion is the total value of Flagship Pioneering Inc.'s 38 reported holdings in Q4 2021. The portfolio turnover from Q3 2021 to Q4 2021 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| MRNA | Moderna Inc | $4,465,227,000 | -34.0% | 17,581,016 | 0.0% | 69.04% | -2.6% | |
| SANA | Sana Biotechnology Inc | $530,020,000 | -31.3% | 34,239,018 | 0.0% | 8.19% | +1.5% | |
| RUBY | Rubius Therapeutics Inc | $372,743,000 | -45.9% | 38,506,526 | 0.0% | 5.76% | -20.1% | |
| Omega Therapeutics Inc | $293,473,000 | -39.9% | 25,902,269 | 0.0% | 4.54% | -11.3% | ||
| FHTX | Foghorn Therapeutics Inc | $289,857,000 | +64.2% | 12,674,120 | 0.0% | 4.48% | +142.3% | |
| EVLO | Evelo Biosciences Inc | $139,793,000 | -13.8% | 23,030,069 | 0.0% | 2.16% | +27.3% | |
| MCRB | Seres Therapeutics Inc | $119,774,000 | +19.7% | 14,378,802 | 0.0% | 1.85% | +76.7% | |
| DNLI | Sell | Denali Therapeutics Inc | $116,851,000 | -15.2% | 2,619,968 | -4.0% | 1.81% | +25.3% |
| KLDO | Kaleido Biosciences Inc | $46,787,000 | -56.2% | 19,575,710 | 0.0% | 0.72% | -35.4% | |
| CDAK | Codiak Biosciences Inc | $29,044,000 | -31.8% | 2,607,303 | 0.0% | 0.45% | +0.7% | |
| SGTX | Sigilon Therapeutics Inc | $28,622,000 | -51.2% | 10,370,369 | 0.0% | 0.44% | -27.9% | |
| AXLA | Axcella Health Inc | $26,227,000 | -29.9% | 12,548,414 | 0.0% | 0.40% | +3.3% | |
| SYRS | Syros Pharmaceuticals Inc | $9,579,000 | -27.1% | 2,938,494 | 0.0% | 0.15% | +7.2% |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
- Flagship Ventures Fund V General Partner LLC #1
- Flagship Ventures Fund IV General Partner LLC #2
- Noubar Afeyan #3
- Flagship Opportunities Fund I General Partner LLC #4
- Flagship Pioneering Special Opportunities Fund II General Partner LLC #5
- Nutritional Health Fund LTP General Partner LLC #6
- Flagship Pioneering Fund VI General Partner LLC #7
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-02-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| SERES THERAPEUTICS INC | 29 | Q3 2023 | 68.0% |
| DENALI THERAPEUTICS INC | 24 | Q3 2023 | 50.9% |
| SYROS PHARMACEUTICALS INC | 24 | Q2 2022 | 27.3% |
| MODERNA INC | 20 | Q3 2023 | 76.9% |
| EVELO BIOSCIENCES INC | 20 | Q1 2023 | 41.2% |
| RUBIUS THERAPEUTICS INC | 18 | Q4 2022 | 60.7% |
| Axcella Health Inc | 17 | Q2 2023 | 3.5% |
| KALEIDO BIOSCIENCES INC | 13 | Q1 2022 | 9.5% |
| Foghorn Therapeutics Inc | 12 | Q3 2023 | 6.5% |
| Sana Biotechnology Inc | 11 | Q3 2023 | 18.4% |
View Flagship Pioneering Inc.'s complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| 4 | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 4 | 2023-09-15 |
| 4 | 2023-08-15 |
| 13F-HR | 2023-08-14 |
| 4 | 2023-07-13 |
| 13F-HR | 2023-05-15 |
| 4 | 2023-02-27 |
| 13F-HR | 2023-02-14 |
View Flagship Pioneering Inc.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.